FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - USD ($) $ in Millions	Apr. 30, 2023	Jan. 31, 2023	Oct. 31, 2022	Apr. 30, 2022	Jan. 31, 2022	Oct. 31, 2021
Liabilities
Contingent Consideration	$ 8	$ 3	$ 67	$ 67	$ 92	$ 89
Fair Value, Measurements, Recurring
Assets
Total assets measured at fair value	604		577
Liabilities
Total liabilities measured at fair value	56		103
Fair Value, Measurements, Recurring | Other Current Assets
Assets
Cash equivalents (money market funds)	526		492
Derivative instruments (foreign exchange contracts)	13		31
Fair Value, Measurements, Recurring | Other assets
Assets
Trading securities	37		31
Other investments	28		23
Fair Value, Measurements, Recurring | Other accrued liabilities
Liabilities
Derivative instruments (foreign exchange contracts)	11		5
Contingent Consideration	7		66
Fair Value, Measurements, Recurring | Other long-term liabilities
Liabilities
Deferred compensation liability	37		31
Contingent Consideration	1		1
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets
Total assets measured at fair value	563		523
Liabilities
Total liabilities measured at fair value	0		0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Assets
Assets
Cash equivalents (money market funds)	526		492
Derivative instruments (foreign exchange contracts)	0		0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other assets
Assets
Trading securities	37		31
Other investments	0		0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other accrued liabilities
Liabilities
Derivative instruments (foreign exchange contracts)	0		0
Contingent Consideration	0		0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other long-term liabilities
Liabilities
Deferred compensation liability	0		0
Contingent Consideration	0		0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Assets
Total assets measured at fair value	41		54
Liabilities
Total liabilities measured at fair value	48		36
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other Current Assets
Assets
Cash equivalents (money market funds)	0		0
Derivative instruments (foreign exchange contracts)	13		31
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other assets
Assets
Trading securities	0		0
Other investments	28		23
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other accrued liabilities
Liabilities
Derivative instruments (foreign exchange contracts)	11		5
Contingent Consideration	0		0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other long-term liabilities
Liabilities
Deferred compensation liability	37		31
Contingent Consideration	0		0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)
Assets
Total assets measured at fair value	0		0
Liabilities
Total liabilities measured at fair value	8		67
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other Current Assets
Assets
Cash equivalents (money market funds)	0		0
Derivative instruments (foreign exchange contracts)	0		0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other assets
Assets
Trading securities	0		0
Other investments	0		0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities
Liabilities
Derivative instruments (foreign exchange contracts)	0		0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities | Resolution Bioscience, Inc.
Liabilities
Contingent Consideration	7		66
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities
Liabilities
Deferred compensation liability	0		0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities | Resolution Bioscience, Inc.
Liabilities
Contingent Consideration	$ 1		$ 1